Physician profile
Laurel Morris
NPI 1245204304
$2,343.63
in general payments reported to CMS, 2019-2025
15 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $79.33 · 2021: $167 · 2022: $306 · 2023: $637 · 2024: $554 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $567.39 | 2019-2025 | Clariti Contact Lens, Cvi Contact Lens |
| Alcon Vision LLC | $343.77 | 2021-2025 | Clareon, Total30 |
| Bausch & Lomb Americas INC. | $316.01 | 2022-2024 | Infuse |
| Oyster Point Pharma, INC. | $222.56 | 2022-2024 | Tyrvaya |
| Harrow Eye, LLC | $151.21 | 2024-2025 | Vevye |
| Genentech USA, INC. | $146.97 | 2024 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $144.90 | 2023 | Syfovre |
| Sight Sciences, INC. | $114.03 | 2022-2023 | Tearcare System |
| Aerie Pharmaceuticals, INC. | $94.50 | 2021 | |
| Sun Pharmaceutical Industries INC. | $79.33 | 2020 | |
| Allergan, INC. | $55.63 | 2019 | |
| Kala Pharmaceuticals, INC. | $40.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $29.75 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $20.44 | 2024 | |
| Abbvie INC. | $17.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurel Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.